Fenwick & West represented AnaptysBio, Inc. (Nasdaq; ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, in its underwritten public offering of 2,530,000 shares of common stock at a public offering price of $94.46 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 330,000 shares of common stock.
Credit Suisse, J.P. Morgan and Jefferies acted as joint book-running managers for the offering. Cantor, Guggenheim Securities and Wedbush PacGrow acted as co-managers.
The Fenwick transaction team included corporate lawyers Rob Freedman, Matt Rossiter, Effie Toshav, Julia Forbess, Michael Shaw and Elena Moreno Cloutier.